Arcturus Therapeutics: Downgrading to "Hold" As CF Program Shifts Population Focus (ARCT)
Arcturus Therapeutics (ARCT) stock downgraded to Hold after disappointing interim data for ARCT-032 in cystic fibrosis. Read the latest analysis on the stock here.
